They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Safety was equally impressive. ENV-294 was well tolerated
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
